TELA Bio, Inc.
- Open
- 0.67
- Day high
- 0.70
- Day low
- 0.67
- Prev close
- 0.69
- Volume
- 27K
- Mkt cap
- $31M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- -1.9
- P/S
- 0.4
- Yield
- —
- Per share
- —
- ▲Insiders net buying $19K over the last 3 months (2 open-market buys, 0 sales)
- 🏛Institutions reducing (13F)
TELA Bio, Inc. (TELA) is a Healthcare company listed on NASDAQ. The stock is down 62% over the past year. Over the trailing 3 months, insiders filed 2 open-market buys and 0 sales (SEC Form 4). Drillr has 1 published research article covering TELA.
TELA Bio, Inc. (TELA) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
TELA earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 10, 2026 | $-0.17 | $-0.20 | -15.1% | $19M | -3.6% |
| May 12, 2026 | $-0.14 | $-0.21 | -50.0% | $19M | +2.5% |
| Mar 24, 2026 | $-0.18 | $-0.16 | +11.1% | $21M | -0.8% |
| Nov 13, 2025 | $-0.17 | $-0.19 | -11.8% | $21M | -1.7% |
| May 8, 2025 | $-0.21 | $-0.25 | -19.0% | $19M | +6.7% |
| Mar 20, 2025 | $-0.24 | $-0.23 | +4.2% | $18M | -16.1% |
| Nov 7, 2024 | $-0.37 | $-0.42 | -13.5% | $19M | -18.2% |
| May 9, 2024 | $-0.48 | $-0.23 | +52.1% | $17M | +1.7% |
| Mar 21, 2024 | $-0.44 | $-0.53 | -20.5% | $17M | +3.7% |
| Nov 9, 2023 | $-0.52 | $-0.45 | +13.5% | $15M | -8.2% |
| May 11, 2023 | $-0.51 | $-0.63 | -23.5% | $12M | -0.9% |
| Mar 21, 2023 | $-0.58 | $-0.52 | +10.3% | $12M | -11.9% |
TELA insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 19, 2026 | Getz Heather Cdirector, officer: Chief Executive Officer | Buy | 12,500 | $0.66 |
| Aug 17, 2026 | Getz Heather Cdirector, officer: Chief Executive Officer | Buy | 15,000 | $0.70 |
| Aug 5, 2026 | Getz Heather Cdirector, officer: Chief Executive Officer | Grant | 500,000 | — |
| Aug 5, 2026 | Getz Heather Cdirector, officer: Chief Executive Officer | Grant | 1,365,000 | $0.74 |
| Aug 5, 2026 | Getz Heather Cdirector, officer: Chief Executive Officer | Grant | 1,005,000 | $0.90 |
| Jul 17, 2026 | Plovanic William J.director | Grant | 20,930 | $0.79 |
| Jul 17, 2026 | Capper Joseph Hdirector | Grant | 6,227 | $0.79 |
| Jun 11, 2026 | THOMAS PAULdirector | Grant | 11,675 | — |
| Jun 11, 2026 | Capper Joseph Hdirector | Grant | 17,335 | $0.94 |
| Jun 11, 2026 | NOHRA GUY Pdirector | Grant | 11,675 | — |
| Jun 11, 2026 | NEELS GUIDO Jdirector | Grant | 17,550 | $0.94 |
| Jun 11, 2026 | THOMAS PAULdirector | Grant | 17,335 | $0.94 |
| Jun 11, 2026 | Capper Joseph Hdirector | Grant | 11,675 | — |
| Jun 11, 2026 | Rocchio Betty Jodirector | Grant | 11,675 | — |
| Jun 11, 2026 | THOMAS PAULdirector | Grant | 17,550 | $0.94 |
Source: TELA SEC Form 4 filings, latest Aug 19, 2026. For informational purposes only — not investment advice.
See the full TELA insider & 13F page →TELA research & analysis
TELA Bio, Inc. company profile
Overview
TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company founded in 2012 and headquartered in Malvern, Pennsylvania. The company went public in November 2019 and specializes in developing and commercializing soft-tissue reconstruction solutions for hernia repair and plastic surgery applications. TELA Bio focuses on providing alternatives to traditional synthetic mesh products by offering reinforced tissue matrices derived from natural ovine (sheep) tissue combined with synthetic materials to optimize patient outcomes while preserving anatomical integrity.
Business
TELA Bio operates in the medical device industry, specifically within the soft-tissue reconstruction market. The company's core business revolves around two primary product families that address different surgical needs. The OviTex Reinforced Tissue Matrix represents the company's flagship hernia repair portfolio. These products are manufactured using ovine rumen (sheep stomach lining) reinforced with polypropylene fibers, creating a biocompatible mesh that integrates with the patient's natural tissue over time. The ovine tissue component gradually remodels into the patient's own tissue, while the polypropylene provides structural support. This hybrid approach aims to combine the strength of synthetic materials with the biocompatibility of natural tissue. The OviTex product line includes various configurations for different types of hernia repairs, including laparoscopic and robotic-assisted procedures, and represents approximately 65-70% of total company revenue. The OviTex PRS (Plastic and Reconstructive Surgery) Reinforced Tissue Matrix addresses the growing market for breast reconstruction and other plastic surgery applications. These products use similar ovine-derived technology but are specifically designed for reconstructive procedures, particularly following mastectomy or other breast surgeries. The PRS segment has shown rapid growth and now accounts for approximately 30-35% of total revenue. The company also offers LiquiFix, a liquid adhesive system for hernia surgery that complements their mesh products, and has expanded internationally, particularly in European markets including the UK, Germany, Netherlands, Austria, and Switzerland.
Revenue model
TELA Bio generates revenue primarily through direct product sales of its medical devices to hospitals and surgical centers. The company employs a direct sales force model, with approximately 70 territory managers and 22 account specialists covering the United States market, plus international distribution partnerships for overseas sales. The company's revenue streams include: 1. Direct hospital sales through their field sales organization, 2. Group Purchasing Organization (GPO) contracts that provide access to large hospital networks, representing 60-70% of total revenue, 3. International sales through distributors in European markets, and 4. A small revenue-sharing component from licensing agreements. Several factors influence TELA Bio's profitability margins. Positive margin drivers include the premium positioning of their products as alternatives to commodity synthetic mesh, which allows for higher average selling prices; the shift in surgeon preference toward natural repair solutions away from permanent synthetic materials; and the expansion of higher-margin PRS products. Negative margin pressures come from the company's reliance on New Zealand-based manufacturing, which subjects them to foreign exchange fluctuations and recently imposed 10% tariffs; intense competition from larger medical device companies with established market presence; the need for extensive sales force investment and surgeon education programs; and the requirement for significant clinical data generation to support product adoption. The company targets long-term gross margins around 70% but currently operates at a loss due to substantial sales and marketing investments required for market penetration.
Competitive moat
TELA Bio operates in a competitive medical device market with limited sustainable competitive advantages. The company's primary differentiator lies in its proprietary ovine-derived technology platform, which combines natural tissue remodeling with synthetic reinforcement. This hybrid approach addresses surgeon concerns about permanent synthetic mesh complications while maintaining structural integrity, positioning TELA Bio favorably amid growing market sentiment against traditional polypropylene mesh products. However, the company's moat is relatively narrow. The technology, while innovative, is not protected by insurmountable patents, and larger medical device companies like Johnson & Johnson, Medtronic, and Boston Scientific possess significantly greater resources for R&D, manufacturing scale, and market access. These established players have existing relationships with hospital systems and can potentially develop competing products or acquire emerging technologies. TELA Bio's clinical data and surgeon relationships provide some defensive positioning, particularly as the company builds evidence through studies like BRAVO II and accumulates real-world outcomes data. The shift toward value-based healthcare and patient-centered decision making could favor their natural repair approach. Additionally, their GPO contracts create some switching costs and market access barriers for competitors. The primary competitive threats come from both traditional synthetic mesh manufacturers who might develop similar hybrid products and emerging biotechnology companies working on next-generation tissue repair solutions. The company's dependence on a single manufacturing partner in New Zealand also creates supply chain vulnerability that competitors with diversified manufacturing could exploit.
Risks & safety
TELA Bio presents a moderate margin of safety profile with mixed financial health indicators. • Liquidity position: Strong with $42.8 million in cash and short-term investments as of Q1 2025, providing approximately 4.4x current liabilities coverage and roughly 1-2 years of operating runway at current burn rates • Cash burn: Significant negative free cash flow of -$9.8 million in Q1 2025, with full-year 2024 free cash flow of -$42.6 million, indicating continued substantial cash consumption • Debt levels: Elevated debt-to-equity ratio of 2.31, though much of this appears to be operational liabilities rather than interest-bearing debt • Valuation metrics: Trading at negative earnings multiples due to losses; Price-to-book ratio of 3.05 suggests modest premium to book value • Revenue trajectory: Positive with 12% year-over-year growth in Q1 2025 and guidance for $85-88 million in 2025 (23-27% growth) • Path to profitability: Management expects flat operating expenses in 2025 while growing revenue, suggesting potential for operating leverage, though profitability timeline remains uncertain
Recent development
Over the past few years, TELA Bio has executed several strategic initiatives to expand its market presence and product portfolio. The company significantly expanded its sales organization from 61 representatives in 2022 to approximately 92 field representatives currently, implementing a new dual-structure approach with territory managers and account specialists to improve market coverage and customer relationships. Product development efforts have focused on expanding configurations and applications. The company launched LiquiFix liquid adhesive system and OviTex IHR (inguinal hernia repair) products in 2024, broadening their hernia repair portfolio. They also introduced larger sizes of OviTex PRS products to address surgeon feedback and expand reconstructive surgery applications. International expansion has been a key growth driver, with European operations growing 67% in Q3 2024 and achieving the first $1 million monthly revenue milestone. The company has strengthened its market access through GPO contract expansion, securing agreements with three national GPOs covering over 6,000 hospitals, with GPO-related revenue now representing 60-70% of total sales. Clinical data generation remains a priority, with ongoing BRAVO II study results and FDA IDE approval for a PRS long-term resorbable breast reconstruction study. Operational challenges have included unexpected sales force turnover, particularly in Q4 2024 when 11 territory managers departed due to competitive recruiting from smaller wound care companies. The company has responded with enhanced compensation plans and refined training programs. Recent tariff implementation on New Zealand-manufactured products presents a new challenge, with management working on mitigation strategies including alternative shipping arrangements.
TELA company profile · for informational purposes only — not investment advice.
Track TELA with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free